𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor

✍ Scribed by Sophie Georgin-Lavialle; Ludovic Lhermitte; Felipe Suarez; Ying Yang; Sébastien Letard; Katia Hanssens; Frédéric Feger; Amédée Renand; Chantal Brouze; Danielle Canioni; Vahid Asnafi; Marie-Olivia Chandesris; Achille Aouba; Paul Gineste; Elizabeth Macintyre; Colin D. Mansfield; Alain Moussy; Yves Lepelletier; Patrice Dubreuil; Olivier Hermine

Book ID
114795680
Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
245 KB
Volume
89
Category
Article
ISSN
0902-4441

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mast cell disease associated with acute
Mast cell disease associated with acute myeloid leukemia: Detection of a new c-kit mutation Asp816His
✍ Vinod A. Pullarkat; Sheeja T. Pullarkat; David C. Calverley; Russell K. Brynes 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB 👁 2 views

Mast cell disease (MCD), a proliferation of mast cells (MC), is occasionally associated with hematologic malignancies. Neoplastic MC have activating c-kit mutations. c-kit is a receptor tyrosine kinase required for the development, proliferation, and survival of MC. Interaction of c-kit with its lig

Effects of AMN107, a novel aminopyrimidi
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit
✍ Srdan Verstovsek; Cem Akin; Taghi Manshouri; Alfonso Quintás-Cardama; Ly Huynh; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 422 KB

Most adults with systemic mastocytosis (SM) carry an activating mutation in the codon 816 of c-kit. We investigated the activity of the new tyrosine kinase inhibitor AMN107 on c-kit mutated mast cell lines and bone marrow samples from patients with SM and compared it to that of imatinib mesylate, a